By submitting this form, you acknowledge that Genentech and its agents may contact you in the future as described in this paragraph, and you certify that you have the necessary authorization to provide the name and email of your colleague for the purposes described herein. Genentech, or its third party vendors and agents, will not use your nor your colleague's personal information or the details of this correspondence for any other purpose than to forward you and your colleague further information on the treatment of acute myocardial infarction. (Please read our complete Privacy Policy to learn more about our use of your information.)

Indication: For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms.

Safety Information: TNKase therapy is contraindicated in the following conditions due to an increased risk of bleeding: active internal bleeding, history of cerebrovascular accident, intracranial or intraspinal surgery or trauma within 2 months, intracranial neoplasm, arteriovenous malformation, or aneurysm, known bleeding diathesis, and severe uncontrolled hypertension.

All thrombolytic agents increase the risk of bleeding, including intracranial bleeding, and should be used only in eligible patients. In addition, thrombolytic therapy increases the risk of stroke, including hemorrhagic stroke, particularly in elderly patients. In patients with large ST segment elevation myocardial infarction, physicians should choose either thrombolysis or percutaneous coronary intervention (PCI) as the primary treatment strategy for reperfusion. Rescue PCI or subsequent elective PCI may be performed after administration of thrombolytic therapies if medically appropriate.